Akebia Therapeutics
AKBA
121 hedge funds and large institutions have $129M invested in Akebia Therapeutics in 2024 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 47 increasing their positions, 19 reducing their positions, and 15 closing their positions.
147% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 19
64% more capital invested
Capital invested by funds: $78.4M → $129M (+$50.5M)
60% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 15
6% more funds holding
Funds holding: 114 → 121 (+7)
2.83% more ownership
Funds ownership: 28.26% → 31.1% (+2.8%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
56% less call options, than puts
Call options by funds: $335K | Put options by funds: $769K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$4.99M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$2.4M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.41M |
| 4 |
Morgan Stanley
New York
|
+$1.22M |
| 5 |
Goldman Sachs
New York
|
+$898K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1.4M |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$230K |
| 3 |
Tudor Investment Corp
Stamford,
Connecticut
|
-$188K |
| 4 |
Squarepoint
New York
|
-$185K |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
-$177K |
AKBA Hedge Fund Activity: Q4 2024 in Review
121 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q4 2024, worth a combined $129M — up 64% from $78.4M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new AKBA positions and 15 closed out — a net gain of 9 holders — while 47 added to existing stakes and 19 trimmed.
The largest buyer was State Street, adding an estimated $4.99M. The largest seller was Jacobs Levy Equity Management, cutting an estimated $1.4M.
- 121 institutional investors held Akebia Therapeutics (AKBA) as of Q4 2024, up from 114 in Q3 2024.
- Funds reported $129M of Akebia Therapeutics stock for Q4 2024, up 64% quarter-over-quarter.
- 24 funds opened new Akebia Therapeutics positions in Q4 2024 and 15 closed out, a net change of +9 holders.
- The largest Akebia Therapeutics buyer in Q4 2024 was State Street, an estimated $4.99M added.
- The largest Akebia Therapeutics seller in Q4 2024 was Jacobs Levy Equity Management, an estimated $1.4M sold.
Based on aggregated 13F filings for Q4 2024.